O
RTHOTOPIC LIVER TRANSplantation (OLT) is typically associated with a large volume of blood loss, resulting in multiple transfusions and related complications. Several recently published studies [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] show little success in predicting the intraoperative blood loss and transfusion requirements despite correlating preoperative clinical and laboratory variables. Transfusion-free surgery is rapidly gaining much needed attention primarily because of the concerns surrounding transmission of diseases such as human immunodeficiency virus, hepatitis C, and other viral infections. 13, 14 Additionally, long-term shortage of blood products and a paucity of alternatives put the system under duress, resulting in cancellation or postponement of elective cases. The intent of this study is to examine the impact of the initiation of the TransfusionFree Medicine and Surgery Program at the University of Southern California University Hospital (USC-UH) in January 2000 for Jehovah's Witnesses (JWs) on the overall use of blood products in non-JW patients undergoing OLT. 15, 16 
METHODS
A total of 365 adult and pediatric OLTs were performed from January 1997 through December 2004 at USC-UH. For consistency, the pediatric and JW transplant recipients were eliminated from this study, leaving only adult non-JW patients, who received either a deceased donor (DD) liver transplant or a living donor (LD) liver transplant (n=272). These patients were categorized into 2 groups based on the initiation of the Transfusion-Free Medi-cine and Surgery Program at USC in January 2000. Group 1 consisted of recipients who received the liver transplant before January 2000. Group 2 included all patients who underwent transplantation after January 2000. Recipients in group 1 underwent OLT without intraoperative blood-saving or salvaging techniques, whereas all transplant recipients in group 2 underwent intraoperative cell salvage (ICS) and acute normovolemic hemodilution (ANH) whenever feasible. The broad term ANH indicates a therapeutic initiative that involves simultaneously removing the patient's blood and replacing it with nonblood products and has been previously described by our team. 17 Rarely, ANH has been used for the DD transplant recipient population. Unlike with the JW patients, this is primarily because we do not have the luxury of preoperatively optimizing every patient going to the operating room before liver transplantation, and there were no protocol-driven regimens for increasing their red blood cell (RBC) mass with erythropoietin. On the other hand, we were able to optimize some of the LD transplant recipients, and 15% underwent ANH. For the purposes of ANH, blood was removed from the central line and drained to a citrate-phosphate-dextrose bag before incision. The volume of blood withdrawn for ANH usually ranged from 400 to 1500 mL, depending on the original hemoglobin level and patient tolerance. In adults, hemoglobin levels decrease 1 g/dL for each unit of blood removed. In our patient population, the lowest hematocrit value after ANH was 21% (range, 21%-26%). Hemodynamic monitoring of heart rate, blood pressure, arterial blood gases, pulmonary artery pressures, central venous pressures, and transesophageal echo to monitor cardiac contractility and ventricular filling are routinely used during the ANH process as a measure of tolerance to the procedure. The ANH blood volume is replaced with 5% albumin and crystalloid solution. The ANH blood is later reinfused during the operation as needed or routinely after liver implantation.
Intraoperative cell salvage is a technique of collecting the operative blood losses that are reinfused after washing. 18 All liver transplantations were performed by the same surgical and anesthesia teams at USC-UH.
The following preoperative data were collected and reviewed: demographic, Child-Pugh score, model of end-stage liver disease (MELD) score, primary diagnosis, type of transplantation, and laboratory data. The MELD score describes survival probability of a patient with end-stage liver disease and is estimated based on the following variables: international normalized ratio, creatinine level, and bilirubin level. were obtained from the USC blood bank. Records were further classified into preoperative (before 6 months of transplantation), intraoperative, and postoperative (after 6 months of transplantation) data. The t test was performed using SAS statistical software, version 8 (SAS Institute Inc, Cary, NC). PϽ.05 was considered statistically significant.
RESULTS
A total of 365 OLTs were performed from January 1997 to December 2004 at USC-UH. Of these, 281 used DD transplants and 84 used LD transplants. After eliminating the pediatric and JW recipients, 272 adult non-JW OLTs were analyzed. Of these, 216 (79.4%) used DD transplants and 56 (20.6%) used LD transplants. There were 172 male (63.2%) and 100 female (36.8%) recipients. The mean ± SD age of the study population was 53±10 years. The primary diagnoses of patients at the time of transplantation were hepatitis C cirrhosis in 78 (28.7%), hepatitis B cirrhosis in 44 (16.2%), autoimmune hepatitis in 35 (12.9%), primary sclerosing cholangitis in 17 (6.2%), primary biliary cirrhosis in 17 (6.2%), and other in 82 (30.0%). Thirty-three OLTs were performed before January 2000 (group 1) and 239 OLTs after that time (group 2).
At the time of transplantation, 111 patients (40.8%) had a MELD score of 25 or higher, and 161 patients (59.2%) had a MELD score of 24 or lower. A total of 85 patients (31.2%) had a MELD score higher than 30. The mean MELD score in group 2 was significantly higher than in group 1 (ie, 19 vs 11) (PϽ.001). Despite the increasing MELD score (Figure 1) , the intraoperative use of PRBCs and FFP was significantly lower in group 2 compared with group 1 (P = .03 and P = .004, respectively) ( Table 1 and Figure 2 ). Platelet use did not appear to be affected.
Preoperative and postoperative use of blood products was also compared. Preoperative requirements in the 6 months before OLT of PRBCs, FFP, and platelets showed no statistical difference for patients in either group (Table 1) . However, there clearly appeared to be a trend toward increased use of preoperative FFP and platelets (Figure 3) , perhaps related to the increased severity of the disease (higher MELD scores). Similarly, the postoperative use of blood products up to 6 months after OLT did not appear to show a statistical difference in the use of blood products between the 2 groups (Table 1) . On further substratification of the patients into groups with MELD scores of above 25 or 25 or below, the results show that the intraoperative number of blood products used in these patients with higher MELD scores had significantly decreased (P =.001) ( Table 2) . 
COMMENT
Liver transplantation for decompensating cirrhosis and unrecoverable acute liver failure is well accepted today and has come to be the standard of care. 19 The operation is still fraught with technical challenges amid a field complicated by coagulopathy and significant portal hypertension. Therefore, colossal intraoperative blood loss that necessitates massive blood transfusion is not unusual, 20 putting the patient and graft at risk and challenging the surgeon. Often these patients are sicker than they look because of additional comorbidities, such as malnutrition, cardiac problems, renal failure, and encephalopathy. The MELD score has pushed most centers, especially on the East and West Coasts, to perform transplantations in much sicker patients than what was done before 2002. This occurrence is seen in our own series, in which more than 30% of our patients had MELD scores higher than 30 (Table 1 and Figure 1 ). Such patients are undoubtedly more complex to treat because they require more transfusions before, during, and after surgery.
The literature is replete with studies aimed at predicting intraoperative need for transfusion and the correlation between the amounts of blood transfused and shortand long-term patient and graft survival. Findlay and Rettke 1 performed a univariate analysis of intraoperative bleeding risk factors in 583 sequential adult patients undergoing OLT. They revealed significant associations between blood transfused and age, sex, primary diagnosis, presence and severity of encephalopathy, creatinine level, bilirubin level, activated partial thromboplastin time, platelet count, mean pulmonary artery pressure, and pseudocholinesterase level. Hendriks et al 2 reported their experience with 164 consecutive OLTs and found that Child-Pugh classification, blood urea nitrogen level, year of transplantation, cold ischemia time, and autologous blood transfusion are independent predic- tors of transfusion requirements. Deakin et al 6 showed that in their population of 300 adult liver transplantations, blood urea nitrogen level and platelet count had an independent correlation with transfusion necessity. Ramos et al 21 showed that only preoperative hemoglobin level, UNOS score, and placement of portocaval shunts predicted the need for blood transfusion. However, much inconsistency occurred in the described preoperative variables, and the literature cites these variables to be poor predictors of intraoperative transfusion requirements and therefore of limited clinical use. 1, 5 On the other hand, it is imperative to take into account that massive intraoperative blood loss is a predictor of not only poor graft outcome but also poor longterm prognosis. 22 Cacciarelli et al 3 reviewed 225 adult OLT recipients and showed a significant improvement in both patient and graft survival when less than 5 U of PRBCs was transfused intraoperatively. Ramos et al 21 showed that even a moderate number of blood transfusions is associated with longer hospital stay and that transfusion of more than 6 U of PRBCs is associated with diminished survival. The Anemia and Blood Tranfusion in the Critically Ill (CRIT) studies by Corwin et al 22 showed that in a setting of 284 intensive care units in the United States, patients who received transfusions had more complications and were at higher risk for mortality.
Excessive use of blood bank resources for liver transplantations puts pressure not only on the transplantation service but also on all other surgical fields. A longterm shortage of blood in hospitals, necessitating tapping into the resources of the Red Cross and other blood donor agencies, is not an unfamiliar setting for every practicing general surgeon. It is an unremitting problem for blood banks throughout the country, leading to delay or cancellation of elective cases, resulting in lost revenue. Heiss et al 23 reported that autologous vs allogeneic blood transfusion decreases the recurrence of curable colon cancer. Allogeneic blood transfusion has been associated with an increased incidence of postoperative bacterial infections. 24 Despite the current conviction among physicians that blood products are safer than they used to be, there are reports of transfusion-related transmission of hepatitis C and human immunodeficiency virus 13, 14 and emerging data of newer pathogens for bovine spongiform encephalopathy and West Nile virus. Blood can almost never be 100% safe. It often takes decades to demonstrate that disease was transmitted through allogeneic blood. For that reason, not only transplantation surgeons but also general surgeons should assume responsibility to minimize overall blood use.
Rapid development of novel drugs is also beginning to play a role in containing coagulopathy and increasing hemopoiesis. Drugs such as human recombinant erythropoietin to increase the pretransplantation RBC mass, aprotinin, 25 tranexamic acid, 26, 27 or ε-aminocaproic acid to inhibit fibrinolysis have now become mainstream strategies. We recently published our data on the utility of the novel drug recombinant factor VIIa in OLTs. Our data provided evidence of the potential usefulness and safety of this agent in the management of coagulopathyrelated oozing. 28 These drugs are not used routinely but rather on a case-by-case basis depending on objective criteria, including coagulation status (aided by a thromboelastogram) and the status of the recipient's kidney function, and subjective criteria, such as excessive oozing at the time of skin incision and unexplained oozing from the raw surfaces after reperfusion. Blood conservation or transfusion-free procedures are more of a complete science, in which the preparation starts preoperatively and continues through the operation and the postoperative phase. It is inappropriate to say that a single drug or solo procedure can obviate the necessity to transfuse. On the contrary, a comprehensive approach to blood conservation should be the norm. Operating room strategies rest not only on the expertise of the surgical team, which is difficult to quantify, but also on ICS and ANH. Intraoperative cell salvage is an effective method for collecting blood from the operative field, where the RBCs are subsequently washed and reinfused. The drawback of ICS is that it salvages only the RBCs and no clotting factors. On the other hand, ANH preserves the integrity of the RBCs and clotting factors, ensuring the availability of safe, fresh, autologous blood. There are, however, a few contraindications to ANH, which include coronary heart disease, significant anemia, and severe pulmonary hypertension. Autotransfusion not only decreases some of the complications of homologous transfusions, such as transmission of unknown pathogens, metabolic derangements, and citrate toxicity, but also helps to preserve blood bank resources and consequently reduces the overall procedure cost. Blood transfusion is also a function of a human component, both on the surgical and anesthesiological front. Surgical skill, the appropriate use of cautery, and specific strategies directed at maintaining low central venous pressure are important factors 2, 28, 29 but difficult to analyze statistically.
We initiated the Transfusion-Free Medicine and Surgery Program at USC in January 2000, initially with the intent of treating JW patients only, which has now slowly expanded to encompass our general surgical practice even outside transplantation. Our experience currently encompasses 30 OLTs in JW recipients with no blood product transfusions, using the principles described herein. [15] [16] [17] This article provides evidence that blood transfusions in non-JW patients, who underwent transplantation after the initiation of the Transfusion-Free Medicine and Surgery Program, show relatively low need for PRBC replacement (6 U) when compared with the existing literature. Our own observations show a decreasing trend in blood use from 1997 to 1999 (Figure 1 ). The use of blood products, however, continues to decline despite the disproportionate increase in MELD scores. We do not believe that this would have been possible without the initiation of appropriate protocols and the TransfusionFree Medicine and Surgery Program. In contrast, in the study by Findlay and Rettke 1 of 583 consecutive liver transplantations, the authors report a mean intraoperative need of 16.4 U of blood, whereas Steib et al 5 describe a range of 5.9 to 18.2 U.
The success in the JW patients encouraged us to apply the same principles in the non-JW patients. Currently, all our patients are operated on with ICS techniques combined with ANH whenever feasible. Despite the increased severity of liver disease of the recipients and (REPRINTED) ARCH SURG/ VOL 141, SEP 2006the constant preoperative transfusion requirements, OLT continues to be successfully performed with the help of bloodless techniques and strategies. We surmise that the development of the Transfusion-Free Medicine and Surgery Program for JW patients has had a positive impact on overall blood use for all recipients undergoing OLT, even in the face of higher MELD scores. Successful decrease in blood use is an upshot of an advanced transfusion-free program.
Surgeons are the leading consumers of blood products, and it is important that we are leaders in promoting transfusion-free techniques. In conclusion, we propose that the recognized need to minimize the use of blood products be elevated to the same level as antibiotic and deep venous thrombosis prophylaxis. 
